1
Proceedings of the National Academy of Sciences, Volume 121, Issue 51, December 2024.
SignificanceDP2, a key anti-inflammatory and antiallergic drug target, particularly in diseases like allergic asthma, remains a focus of intense therapeutic interest. Despite several DP2-targeted drugs reaching clinical trials, none has been approved yet…
Source : National Academy of Sciences